Immunoglobulin G - ADMA Biologics

Drug Profile

Immunoglobulin G - ADMA Biologics

Alternative Names: Bivigam; Immunoglobulin liquid intravenous - Biotest Pharmaceuticals; IVIG - Biotest Pharmaceuticals; IVIG - Nabi Biopharmaceuticals; NABI-IVIG

Latest Information Update: 30 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nabi Biopharmaceuticals
  • Developer Biotest Pharmaceuticals; Kedrion
  • Class Immunoglobulin isotypes
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Immunodeficiency disorders

Most Recent Events

  • 30 Jul 2018 US FDA acknowledges receipt of Prior Approval Supplement filing for review
  • 26 Jul 2018 ADMA Biologics plans to relaunch immunoglobulin G (BIVIGAM®) in first quarter of 2019
  • 26 Jul 2018 FDA assigns PDUFA action date of 25/10/2018 for immunoglobulin G
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top